Dummer Dummer R R Ascierto Ascierto PA PA Gogas Gogas HJ HJ Arance Arance A A Mandala Mandala M M Liszkay Liszkay G G Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Lancet Oncol Lancet Oncol 2018 2018 19 19 5 5 603 603 615 615 10.1016/S1470-2045(18)30142-6 10.1016/S1470-2045(18)30142-6 29573941 29573941. The gene discussed is BRAF; the disease is melanoma.